ライフサイエンスコーパス: hypersomnolence

1 leepiness Scale (ESS, which assesses daytime hypersomnolence).

2 sential for the proinflammatory response and hypersomnolence.

3 of superoxide in the oxidation injury and in hypersomnolence.

4 ysis was used to assess the risk factors for hypersomnolence.

5 stages, was also an independent predictor of hypersomnolence.

6 d slow wave sleep (SWS) were protective from hypersomnolence.

7 o significant association with the degree of hypersomnolence.

8 treatment for narcolepsy and other types of hypersomnolence.

9 option in patients with treatment-refractory hypersomnolence.

10 decreased sleep efficiency, without daytime hypersomnolence.

11 pitolisant to be effective in treating both hypersomnolence and cataplexy while generally being well

12 obstructive sleep apnea, results in lasting hypersomnolence and is associated with nitration and oxi

13 itical role for NADPH oxidase in the lasting hypersomnolence and oxidative and proinflammatory respon

14 A positive association between hypersomnolence and oxyhemoglobin desaturation (DeltaSaO

15 to not only long-term hypoxia/reoxygenation hypersomnolence but also to carbonylation, lipid peroxid

16 cterize the prevalence of persistent daytime hypersomnolence, difficulties initiating and maintaining

17 Idiopathic hypersomnia is a central hypersomnolence disorder mainly characterised by excessi

18 pnoea syndrome, circadian disorders, central hypersomnolence disorders (narcolepsy and idiopathic hyp

19 ntiation with CSF from patients with central hypersomnolence disorders, with no significant differenc

20 and narcolepsy, a disorder characterized by hypersomnolence during normal wakefulness.

21 olysomnographic parameters and the degree of hypersomnolence in 741 patients with SDB (apnea-hypopnea

22 ry responses, oxidative injury, and residual hypersomnolence in obstructive sleep apnea.

23 ragmentation are independent determinants of hypersomnolence in SDB.

24 and activity monitoring revealed a profound hypersomnolence in these mice.

25 Persistent daytime hypersomnolence is associated with significant morbidity

26 Disrupted sleep, including daytime hypersomnolence, is a core symptom reported by primary b

27 nal hypoxemia were independent predictors of hypersomnolence (MSLT < 10 min).

28 ols (9 males and 6 females) with unspecified hypersomnolence (n = 7) and miscellaneous neurological c

29 tween genetics and some central disorders of hypersomnolence - narcolepsy types 1 and 2 (NT1, NT2), i

30 derate-severe sleep apnea, result in lasting hypersomnolence, oxidative injury, and proinflammatory r

31 RPC6, PNOC), and genes suggesting an obesity-hypersomnolence pathway (PNOC, PATJ).

32 g with breakfast and lunch, in patients with hypersomnolence syndromes (excluding narcolepsy with cat

33 Some central hypersomnolence syndromes are associated with a positive

34 Hypersomnolence was quantified with the multiple sleep l

35 crease in stage 2 or SWS the adjusted RR for hypersomnolence were 0.93 and 0.79, respectively.

36 The adjusted relative risks (RR) of hypersomnolence were 1.00, 1.30, and 1.65 for patients w

37 p a mouse model of cranial radiation-induced hypersomnolence which recapitulates the human experience